Head-to-head review

Ro (Body) vs Henry Meds

Ro (Body) and Henry Meds both compete for patients searching for a GLP-1 weight-loss program. This head-to-head compares pricing, medications, insurance handling, and clinician quality so you can pick the right fit.

Editorial verdict

Ro (Body) wins on starting price at $145/mo. Choose Ro (Body) if you want to run brand-name medication through commercial insurance. Pick the program whose medications and care model best match your treatment plan.

Side-by-side comparison

Every attribute scored head-to-head. The highlighted cell is our pick for that row.

Attribute
Ro (Body)
Henry Meds
Editor rating

Ro (Body)

4.4 / 5

Henry Meds

4.4 / 5
Starting price

Ro (Body)

$145/mo

Henry Meds

$297/mo
Category

Ro (Body)

Telehealth GLP-1

Henry Meds

Compounded GLP-1
Medications

Ro (Body)

  • Wegovy
  • Zepbound
  • Saxenda
  • Compounded Semaglutide

Henry Meds

  • Compounded Semaglutide
  • Compounded Tirzepatide
  • Oral Semaglutide
State coverage

Ro (Body)

All 50 states

Henry Meds

All 50 states
Insurance accepted

Ro (Body)

Yes

Henry Meds

No
Shipping included

Ro (Body)

No

Henry Meds

Yes
Cancel anytime

Ro (Body)

Yes

Henry Meds

Yes

Ro (Body)

4.4

Brand-name Wegovy & Zepbound through insurance

Ro Body is the established telehealth player that pairs a polished UX with the operational muscle to actually move brand-name GLP-1 prescriptions through pharmacies and insurance.

Pros

  • Helps navigate insurance for brand-name GLP-1s
  • Polished mobile app and tracking
  • Access to compounded alternatives if insurance denies

Cons

  • Medication cost is separate when using insurance
  • Backorders on Wegovy and Zepbound can delay starts
Read full Ro (Body) review

Henry Meds

4.4

Flat-rate compounded semaglutide & tirzepatide

Henry Meds pioneered the flat-rate compounded GLP-1 model and remains a default pick for patients who want pricing certainty through every titration step.

Pros

  • Flat monthly price regardless of dose
  • Async visits keep wait times short
  • Sublingual option for needle-averse patients

Cons

  • Pricier than newer compounded entrants
  • No insurance pathway for brand-name medications
Read full Henry Meds review

Other head-to-head reviews

Cost, coverage & condition context

Use these resources to pressure-test which program fits your budget, insurance, and clinical situation.